Pre-market -7.69%: 9G2.SI Singapore Inst. of Advanced Med. (SES) Feb 2026: watch cash

Pre-market selling has knocked 9G2.SI stock down 7.69% to S$0.048 as of the pre-market session on 18 Feb 2026. Volume at 4,508,900 shares shows heavier trading than some recent sessions and points to urgent focus on liquidity. Singapore Institute of Advanced Medicine Holdings Ltd. (9G2.SI) trades on the SES in SGD and sits well below its 50-day average of S$0.062. For top losers in this pre-market window, we track cash ratios, debt metrics and the Meyka AI forecast to assess near-term downside risk and recovery triggers.

9G2.SI stock: market snapshot and price action

The stock opened at S$0.051 and has a day range of S$0.046–S$0.052 in pre-market trade on 18 Feb 2026. One-day change is -7.69% with a year high of S$0.089 and year low of S$0.026. This drop places 9G2.SI among pre-market top losers on the SES and reflects short-term selling pressure rather than company news.

9G2.SI analysis: fundamentals and liquidity risks

Singapore Institute of Advanced Medicine Holdings Ltd. reports EPS -0.03 and PE -1.6, highlighting current unprofitability. The company shows current ratio 0.31 and debt to equity 1.05, which signals tight short-term liquidity and above-average leverage for the Healthcare sector. Book value per share is S$0.052, comparable to the current price and flagging valuation risk if operating losses persist.

9G2.SI stock technicals and trading signals

Momentum indicators show an RSI 56.97 with ADX 46.97, suggesting a strong short-term trend. Price sits below the 50-day average (S$0.06156) but above the 200-day average (S$0.04229), creating mixed technical signals. Traders should note the avg volume 5,532,107 versus current volume 4,508,900, a relative volume of 0.82 that tempers but does not erase the pre-market move.

Meyka AI rates 9G2.SI with a score out of 100: grade and model forecast

Meyka AI rates 9G2.SI with a score of 60.99 out of 100, grade B and suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of S$0.106 versus the current S$0.048, implying +121.05% upside. Forecasts are model-based projections and not guarantees.

9G2.SI stock valuation and analyst lens

Key ratios include PB 0.92 and price to sales 3.20, which show the stock trades near book but with weak margins. Return on equity is -41.93% and operating cash flow per share is negative, pointing to poor profitability. Given those metrics, realistic near-term price targets from a risk-aware analyst are S$0.03–S$0.09, depending on cash improvements and margin recovery.

Trading outlook and sector context for 9G2.SI stock

Healthcare sector performance has been modest year-to-date, and smaller care facilities names face funding and margin pressure. For 9G2.SI, watch working capital changes, receivables days and any capital raise. A break below S$0.046 would increase downside risk, while reclaiming S$0.062 (50-day average) supports a short-term stabilization thesis.

Final Thoughts

9G2.SI stock is a pre-market top loser on 18 Feb 2026 after a 7.69% decline to S$0.048, driven by thin liquidity and negative profitability metrics. Fundamentals show current ratio 0.31, debt to equity 1.05, EPS -0.03, and negative operating cash flow per share, which justify caution for investors. Meyka AI’s model projects a yearly S$0.106 forecast, implying ~121.05% upside from the current price, but that projection assumes margin recovery and improved cash flow. Short-term traders should treat breaks below S$0.046 as increased risk, while medium-term holders may track the S$0.03–S$0.09 analyst target band and any financing updates. Use this as data-driven market analysis from an AI-powered market analysis platform and not as personal financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.